Global expansion Nova Biomedical is a global leader with customers in more than 100 countries and recently expanded through a strategic alliance to strengthen bioprocessing and clinical diagnostics capabilities, signaling growth opportunities across international accounts and new market segments.

Integrated product portfolio A combined offering across clinical diagnostics, bioprocessing, and veterinary diagnostics creates cross-sell opportunities for labs and hospitals seeking end‑to‑end solutions, as well as bundled deployments that improve workflow efficiency.

Strategic partnerships Recent and ongoing collaborations, including with Paia Biotech and the NanoCellect assets, indicate a drive to accelerate product development and time‑to‑value in cell line development and quality assessment, presenting channels for co‑selling and alliance-based deals.

Investment in R&D Continual reinvestment in R&D fuels a strong pipeline of high‑performance technologies, suggesting recurring upgrade opportunities, long‑term service contracts, and early access to next‑gen analyzers for existing bioprocessing and IVD customers.

Security and resilience A cybersecurity incident in 2025 underscores the importance of robust security and business continuity offerings; sales plays can position Nova as a partner delivering secure, compliant diagnostics and data integrity solutions to protect hospital and lab operations.